Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US.
The goal of this study was to estimate prevalence of HER-2 positive tumors in a population-based sample of 1026 women diagnosed in 2005 with early stage breast cancer. We modeled the relationship between patient and tumor characteristics and HER-2. HER-2 positive estimates were 19% for women aged ≤ 49 years and 15% aged ≥ 50 years. HER-2 varied by tumor grade and size in women aged ≤ 49 years but was not significant in multivariate analysis. Tumor grade and race were associated with HER-2 for women aged ≥ 50 years after controlling for other variables. HER-2 varies by age and by race and tumor in older women.
DECLARATION OF INTEREST The authors report no conflict of interest. The authors alone are responsible for the content and writing of this paper.
15 references, click to expand
-
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.J Clin Oncol. 2006 Jul 1;24(19):3032-8 PMID: 16809727
-
Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer.Ann Oncol. 2005 Nov;16(11):1755-61 PMID: 16085689
-
Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program.Breast Cancer Res Treat. 2009 Jan;113(1):189-96 PMID: 18256926
-
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science. 1987 Jan 9;235(4785):177-82 PMID: 3798106
-
Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.J Clin Oncol. 1992 Jul;10(7):1049-56 PMID: 1351538
-
Race modifies the association between breast carcinoma pathologic prognostic indicators and the positive status for HER-2/neu.Cancer. 2005 Nov 15;104(10):2189-96 PMID: 16208704
-
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.Science. 1989 May 12;244(4905):707-12 PMID: 2470152
-
HER-2/neu amplification predicts poor survival in node-positive breast cancer.Cancer Res. 1990 Jul 15;50(14):4332-7 PMID: 1973070
-
Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.Breast Cancer Res Treat. 2005 May;91(1):81-7 PMID: 15868434
-
Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.J Natl Cancer Inst. 2002 Jun 5;94(11):852-4 PMID: 12048273
-
Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.J Clin Pathol. 2005 Jun;58(6):611-6 PMID: 15917412
-
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.J Natl Cancer Inst. 2003 Jan 15;95(2):142-53 PMID: 12529347
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.N Engl J Med. 2005 Oct 20;353(16):1659-72 PMID: 16236737
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.N Engl J Med. 2005 Oct 20;353(16):1673-84 PMID: 16236738
-
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.JAMA. 2006 Jun 7;295(21):2492-502 PMID: 16757721
Contact
No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong
Qilu Normal University · Genelibs Bioinformatics Lab
750 Shunhua Rd, Jinan
2F, Bldg F, University Science Park
Tel: 0531-88819269
WeChat Official Account
Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.
Business Email
E-mail: product@genelibs.com
Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2
